Niu Yongzhi, Huang Yichuan, Dong Anbing, Sun Yinghe
Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, People's Republic of China.
Int J Gen Med. 2022 Feb 15;15:1509-1516. doi: 10.2147/IJGM.S338564. eCollection 2022.
Identification of novel biomarkers could benefit the clinical therapy and management of papillary thyroid carcinoma (PTC). Human endogenous retrovirus long terminal repeat-associating protein 2 (HHLA2) has been reported to play roles in the development of various cancers. The clinical significance and biological function of HHLA2 in PTC were investigated.
The expression level of HHLA2 was evaluated in PTC tissues (from 107 PTC patients) and cell lines (TPC-1, IHH-4, CGTH-W3, and MDA-T32 cells) by RT-qPCR. The clinical significance of HHLA2 was estimated with a series of statistical analyses. The biological function of HHLA2 was assessed with the CCK8 assay and transwell assay.
HHLA2 was upregulated in PTC compared with the normal samples and was associated with the positive lymph node metastasis and advanced TNM stage of PTC patients. HHLA2 was an independent prognostic factor associated with the poor survival of PTC patients. Additionally, HHLA2 functioned as a tumor promoter that enhanced the progression of PTC cells.
HHLA2 could serve as a prognostic biomarker and tumor promoter in PTC, providing a novel therapeutic target of PTC.
鉴定新型生物标志物有助于甲状腺乳头状癌（PTC）的临床治疗与管理。据报道，人类内源性逆转录病毒长末端重复序列相关蛋白2（HHLA2）在多种癌症的发生发展中发挥作用。本研究旨在探讨HHLA2在PTC中的临床意义及生物学功能。
采用RT-qPCR检测107例PTC患者的肿瘤组织及TPC-1、IHH-4、CGTH-W3和MDA-T32细胞系中HHLA2的表达水平。通过一系列统计学分析评估HHLA2的临床意义。采用CCK8法和Transwell法评估HHLA2的生物学功能。
与正常样本相比，PTC中HHLA2表达上调，且与PTC患者的阳性淋巴结转移及TNM分期相关。HHLA2是PTC患者预后不良的独立预后因素。此外，HHLA2作为肿瘤促进因子，可促进PTC细胞的进展。
HHLA2可作为PTC的预后生物标志物和肿瘤促进因子，为PTC提供了新的治疗靶点。
